In the present work, an iTRAQ-based high-throughput quantitative proteomics technique was used to evaluate molecular context-dependent responses to different HSP90 inhibitors and to identify proteins that could potentially be used as biomarkers of the response to inhibition of this chaperone in lung adenocarcinoma. This evidence concerns the gene HSP90AB1 and lung adenocarcinoma.